Abstract: The present invention pertains in general to the field of the stabilization of gonadotropin formulations, in particular liquid formulations of gonadotropins. The stabilization is achieved by a particular combination of excipients, preferably arginine and methionine. In a preferred embodiment, the formulation does not comprise a buffer.
Type:
Grant
Filed:
February 24, 2017
Date of Patent:
October 6, 2020
Assignee:
Ferring B.V.
Inventors:
Helen Ulrika Sjögren, Charlotte Højer-Pedersen
Abstract: The present invention provides a method for the diagnosis of disorders caused by foetal alcohol syndrome, said method comprising the assaying of PLGF (placental growth factor).
Type:
Grant
Filed:
June 22, 2016
Date of Patent:
October 6, 2020
Assignees:
Centre Hospitalier Universitaire De Rouen, Universite de Rouen Normandie, Institut National De La Sante Et De La Recherche Medicale (INSERM)
Inventors:
Bruno José Gonzalez, Stéphane Marret, Matthieu Jean Alexandre Lecuyer, Annie Laquerriere, Soumeya Bekri, Céline Lesueur, Sylvie Marguerite Alberte Jegou, Pascale Yvonne Joséphine Marcorelles
Abstract: The present invention relates to novel agonistic anti-TrkB antibodies and therapeutic and diagnostic methods and compositions for using the same.
Type:
Grant
Filed:
June 7, 2018
Date of Patent:
October 6, 2020
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Rolf Herrmann, Remko Alexander Bakker, Sebastian Bandholtz, Peter Michael Benz, Michael Dziegelewski, Lore Florin, Cynthia Hess Kenny, Sarah Low, Holger Rosenbrock, Sanjaya Singh, Heiko Friedrich Stahl, Sathyadevi Venkataramani, Vladimir Voynov, Haiguang Xiao
Abstract: The present invention relates to Anti-Mullerian Hormone (AMH) neutralizing antibodies and their use in the field of reproduction.
Type:
Grant
Filed:
September 23, 2016
Date of Patent:
September 15, 2020
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS DIDEROT—PARIS 7, UNIVERSITE PARIS—SUD
Inventors:
Nathalie Di Clemente-Besse, Nathalie Josso, Richard Cate, Corinne Belville
Abstract: The present invention relates to treatment of neurological diseases such as multiple sclerosis (MS) and Alzheimer's disease, using an estrogen receptor beta (ER?) ligand.
Type:
Grant
Filed:
September 1, 2015
Date of Patent:
September 1, 2020
Assignee:
The Regents of the University of California
Abstract: A method of tolerance to narcotics in a patient in need thereof comprises administering a botulinum toxin to the patient. The botulinum toxin is selected from the group consisting of botulinum toxin type A, botulinum toxin type B, botulinum toxin type C, botulinum toxin type D, botulinum toxin type E, botulinum toxin type F and botulinum toxin type G, a fragment thereof, a hybrid thereof, a chimera thereof, and a combination thereof. The botulinum toxin may be administered by subcutaneous/intradermal injection. The subcutaneous/intradermal injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, and a sacral nerve of the patient. The therapeutically effective amount of the botulinum toxin administered is between about 1 unit and about 150 units.
Abstract: A method of treating ASD (autism) in a patient in need thereof comprises administering a botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous/intradermal injection. The subcutaneous/intradermal injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, and a sacral nerve of the patient. In infants or toddlers—from about 1 to 5 year olds, it is used to prevent or minimize damage to the developing brain; in older children and adult Autism Spectrum Disorder (ASD) patients, it will be used to reduce or eliminate their symptoms.
Abstract: The invention relates to antibodies directed against follicle-stimulating hormone (FSH) and capable of potentiating the bioactivity of gonadotropins.
Type:
Grant
Filed:
September 10, 2015
Date of Patent:
July 7, 2020
Assignee:
IGYXOS
Inventors:
Elodie Kara, Jeremye Decourtye, Sophie Casteret, Marie-Christine Maurel
Abstract: The present invention relates to methods of improving blastocyst implantation by delivering adrenomedullin to the endometrium of a subject. The invention further relates to methods of performing in vitro fertilization.
Type:
Grant
Filed:
December 8, 2016
Date of Patent:
June 9, 2020
Assignee:
The University of North Carolina at Chapel Hill
Abstract: Methods and compositions for synchronizing the time of insemination in swine are described. More particularly, methods are described for synchronizing the time of insemination by administration of a composition comprising a hormone, wherein the swine is inseminated only one time after administration of the hormone, and wherein there is no heat detection.
Abstract: Disclosed are specific biomarkers that allow for early testing of preeclampsia/HELLP syndrome. Thus, a method is provided predicting preeclampsia in a pregnant woman. Also disclosed is a kit comprising means for assaying a sample from a pregnant woman for the concentrations of the specific biomarkers.
Type:
Grant
Filed:
June 13, 2013
Date of Patent:
June 2, 2020
Assignees:
Wayne State University, The United States of America as represented by The Secretary, Department of Health and Human Services Office of Technology Transfer, National Institutes of Health, Semmelweis University, Genesis Theranostix Korlatolt Felelossegu Tarsasag
Inventors:
Adi L. Tarca, Nandor Than, Gabor Juhasz, Adrienna Katalin Kekesi, Hamutal Meiri, Zoltan Papp, Roberto Romero
Abstract: The present description relates to a method for determining the risk of a pregnant woman with chronic hypertension developing early or late onset pre-eclampsia. The present description provides methods useful for determining risk that a pregnant individual with chronic hypertension will develop an early pre-eclampsia or late pre-eclampsia. Useful combination of biochemical markers including PlGF and sP-Selectin and related clinical population studies are described herein.
Type:
Grant
Filed:
September 1, 2015
Date of Patent:
May 19, 2020
Assignee:
Wallac Oy
Inventors:
Tarja Ahola, Heikki Kouru, Mikko Sairanen
Abstract: A method for identifying a patient that is at risk for developing a thyroid disorder that occurs subsequent to treatment with a regimen that depletes lymphocytes, comprising determining whether antibodies directed against thyroid peroxidase or thyroid microsomes are present in the patient, wherein if the antibodies are present in the patient then the patient is at increased risk for developing a thyroid disorder. A particular embodiment is a method for identifying a patient with multiple sclerosis that is at risk for developing a thyroid disorder that occurs subsequent to treatment with a regimen that depletes CD52-positive cells, comprising determining whether antibodies directed against thyroid peroxidase or thyroid microsomes are present in the patient, wherein if the antibodies are present in the patient then the patient is at risk for developing the thyroid disorder.
Abstract: Described herein are methods, assays, and compositions relating to the treatment of thrombosis, preeclampsia, cancer, and intestinal inflammation, e.g., by administering ADAMTS13 to a subject in need of treatment.
Abstract: The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, including post-partum auto immune diseases. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of these Th1-mediated (cell-mediated) autoimmune diseases known to either have an initial onset following the birth of a child or which are exacerbated in patients in the post-partum period.
Type:
Grant
Filed:
August 24, 2017
Date of Patent:
April 7, 2020
Assignee:
The Regents of the University of California
Abstract: Provided herein are methods for detecting an increased probability or risk of neurodegeneration in a subject. In some embodiments the method comprises assaying a sample from the subject for lysozyme and/or cathepsin S and detecting the lysozyme and/or cathepsin S from the sample, wherein an increased lysozyme and/or cathepsin S compared to levels in a control subject sample indicate an increased probability or risk of neurodegeneration. Methods of treatment and screening assays for determining drug effectiveness are also provided herein.
Abstract: The present invention relates to methods, compositions and kits for controlling, managing or manipulating the non-human mammalian female reproductive cycle. The methods include oestrus induction and/or synchronisation, induction of ovulation and/or superovulation and optionally further includes a method of providing an immunopermissive uterine environment prior to insemination or implantation of embryos.
Type:
Grant
Filed:
October 4, 2016
Date of Patent:
March 17, 2020
Assignee:
Ostara Biomedical Ltd.
Inventors:
Nicolas Michel Orsi, Nadia Gopichandran, David Andrew Brooke
Abstract: The invention relates to antibodies directed against follicle-stimulating hormone (FSH) and capable of potentiating the bioactivity of gonadotropins.
Type:
Grant
Filed:
September 10, 2015
Date of Patent:
March 10, 2020
Assignee:
REPROPHARM VET
Inventors:
Elodie Kara, Jeremye Decourtye, Sophie Casteret, Marie-Christine Maurel